Chapter 35: Alterations of the Female Reproductive System

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome to the Deep Dive, where we plunge into complex topics to bring you the most critical, surprising, and truly actionable insights.

Glad to be here.

Today, we're navigating the incredible complexity of the female body.

It's a system so intricately balanced, you know?

Absolutely, and that delicate balance can easily be disrupted, leading to just a huge range of health concerns.

That's our focus today.

That's right.

Our deep dive is into Chapter 35, Alterations of the Female Reproductive System, from Understanding Pathophysiology, Seventh Edition.

And our goal here.

Well, we want to cut through the density and give you a clear, accessible overview of the really key concepts, mechanisms, clinical examples, basically the need to know stuff from this chapter.

Like a shortcut.

Exactly.

A shortcut to understanding everything from developmental abnormalities and puberty timing right through to hormonal issues, infections, growths, cancers, and even challenges with sexual function and fertility.

These can definitely be sensitive topics.

They can be, but they're so crucial for understanding female health, self -concept, quality of life.

We'll go step -by -step, using clear language, and we'll try to describe the key visuals from the text so you can picture what's going on.

Okay, let's dive in.

Starting with abnormalities of the female reproductive tract,

what's the basic plan for normal development, and, you know, where does it sometimes go wrong?

Okay, so fundamentally, normal female reproductive development hinges on two main things during fetal life.

First, the absence of testosterone, and second, the proper fusion of these structures called the parmesanephric ducts, or malorian ducts.

They basically merge to form the uterus and cervix, and the far ends become the fallopian tubes.

So errors happen when?

When cells don't respond to hormones correctly or they don't migrate to the right place during that fusion process.

That's when you get these structural variations.

Androgen insensitivity syndrome, AIS, that's a really striking example you mentioned.

It sounds like quite a paradox.

It really is.

AIS is an X -linked genetic thing.

It affects the cell's androgen receptors.

Just think of them like docking stations for male hormones like testosterone.

Okay.

If those docking stations are broken because of the mutation,

the cells just can't respond to testosterone.

So the paradox is, you have someone who is genetically male XY karyotype, but they develop looking externally female.

Wow.

So genetically male, physically female, what does that actually look like?

Well in complete AIS, see AIS, the body can't use androgens at all.

So you get external female characteristics, but internally there's no uterus.

Meaning no periods and infertility.

Exactly.

And they do have testes, usually internal, sometimes palpable.

Breast development is typically normal, but pubic and axillary hair is often quite sparse.

And it's good to remember there are milder forms too with a range of presentations.

And what about problems specifically with those malaria ducts?

Right.

Those are structural abnormalities of the uterus cervix tubes.

Often it's a mixed genetics plus maybe environmental factors messing with cell migration during development.

Can you describe some examples like what would we see if we could look at figure 35 .1 from the text?

Sure.

So imagine the typical pear shaped uterus.

Now picture variations.

You might see a double uterus with a double vagina like two separate systems side by side.

Or a bicornuate uterus which looks kind of heart shaped with two horns at the top.

Okay.

Then maybe a uterus with a midline septum like a wall down the middle.

Or a unicornuate uterus that's smaller, only connected to one fallopian tube, almost like just half the uterus developed properly.

Those are significant differences.

How would someone even know they have this?

Often they don't find out until they run into problems with infertility or recurrent miscarriages.

They might menstruate normally but carrying a pregnancy can be tough.

Is there anything that can be done?

Yeah.

Sometimes surgery can correct some of these structural issues which can definitely improve the chances for a successful pregnancy.

Okay.

Shifting from how the tract forms to how it matures.

Let's talk alterations of sexual maturation.

Puberty is such a big transition.

What happens if the timing is off?

Right.

Puberty.

It's this whole process developing secondary sex characteristics, growth spurt, getting reproductively capable.

It's complex, influenced by genes, environment.

And the timing seems to be changing.

Yeah.

There's definitely an observed trend towards earlier onset in girls.

Now typically between 8 and 13 years.

And interestingly it seems particularly linked to obesity, mostly affecting breast development earlier, but not necessarily the first period or menage.

Okay.

So delayed puberty, that's when things don't start by a certain age.

Exactly.

For girls, the definition is no vilage, that's breast development, by age 13 or no menstruation by age 15.

What causes that delay?

Well, the most common reason is actually just a physiologic delay, what they call constitutional delay.

Everything's normal.

The hormone axis is intact.

It just happens later.

Often runs in families.

But less commonly, it could be due to disruptions in that HPG axis, the hypothalamic pituitary gonadal axis, or other things like Turner syndrome, CNS issues, even severe chronic illness or anorexia.

And the flip side, precocious puberty, starting too early.

Right.

That's defined as signs like breast or pubic hair development appearing before age 8.

What triggers that?

It can be central, meaning the brain signals just start too soon, often for unknown reasons, or sometimes due to CNS disorders, or it can be peripheral, where other parts of the body, like the adrenals or ovaries, start releasing hormones independently.

The chapter also mentions endocrine disruptors here, right, in a did -you -know box.

Yes, exactly.

That's a really fascinating area.

There's growing concern about endocrine disrupting chemicals, EDCs, things in the environment, like certain pesticides or industrial compounds that can mimic or interfere with our natural hormones.

And potentially influence puberty timing.

Potentially, yes.

Yeah.

It's complex, but things like obesity, certain hormone levels like leptin and these EDCs are all part of the picture researchers are looking at.

The main thing is, if precocious puberty is suspected,

evaluation and treatment are key to find or rule out an underlying cause and manage development.

Okay, let's move into the main section.

Disorders of the female reproductive system, starting with hormonal and menstrual alterations, painful periods,

primary dysmenorrhea.

So many women experience this.

What's actually going on?

Yeah, it's incredibly common, affects maybe up to 90 % of women.

The key thing about primary dysmenorrhea is that it's painful menstruation without an underlying pelvic disease like endometriosis.

So what causes the pain itself?

It really comes down to excessive levels of certain chemicals called prostaglandins, specifically PGF2 and PGE2.

These are potent.

They make the uterine muscle contract very strongly, they constrict blood vessels in the uterus and they make nerve endings more sensitive.

So it's like intense cramping, reduced blood flow and heightened pain signals all at once.

Exactly.

That ischemia, the lack of blood flow, contributes to the pain.

And because these prostaglandins can get into the general circulation.

Ah, that explains the other symptoms.

Right.

The pelvic pain often radiates to the groin or back and you can get systemic stuff like vomiting, diarrhea,

sometimes even headaches or feeling faint.

All thanks to those circulating prostaglandins.

Makes sense.

So treatment focuses on reducing them.

Precisely.

NSAIDs work because they inhibit QOEX enzymes,

which are needed to make prostaglandins.

Hormonal contraceptives help by preventing ovulation, which dramatically lowers prostaglandin levels during the cycle.

Okay.

Now, amenorrhea,

the absence of periods, what's the distinction between primary and secondary?

Good question.

Primary amenorrhea is when men arc, the first period never happens.

Either by age 13, if there are also no secondary sex characteristics like breast development or by age 15, regardless of other developments.

The secondary.

Secondary amenorrhea is when a woman has had periods before, but then they stop for three or more consecutive cycles.

What are the common culprits?

Well, the very first thing to rule out always is pregnancy.

After that, common causes include thyroid disorder, especially hypothyroidism or hyperlactin levels.

Interruptions to that whole HPO axis, hypothalamic, pituitary ovarian are also key.

Think excessive exercise, significant stress, major weight loss, and PCOS is a big one too.

The chapter has a figure, figure 35 .2, outlining causes.

What's the diagnostic approach like?

Yeah, that figure shows a kind of flow chart.

It emphasizes ruling out pregnancy and thyroid issues first, then looking at prolactin levels, than FSHLH to check ovarian and pituitary function, and considering androgen levels if PCOS is suspected.

Treatment really depends on correcting the underlying cause.

Got it.

Let's talk abnormal uterine bleeding, AUB, sounds like a bit of a catch -all term.

It is, and it's super common, maybe a third of all gyno visits.

AUB just means bleeding.

That's often in terms of duration, volume, frequency, or irregularity, and it's been going on for at least six months.

The terminology has changed, right?

Table 35 .2?

Yes, thankfully.

We now use clearer terms.

Instead of vague things like menorrhagia, we say heavy menstrual bleeding, HMB.

Bleeding between periods is intermenstrual bleeding, IMB.

It helps standardize things.

And there's a system to classify the causes.

Polymcoin.

Right, the polymcoin system.

Figure 35 .3 lays this out nicely.

Think of it like this.

Polym covers the structural causes you might see on imaging, or biopsy polyps, adenomonosis, gliomaeomas, fibroids, and malignancy hyperplasia.

Okay, structural causes.

Then co -eying covers the non -structural causes, coagulopathy, bleeding disorders, ovulatory dysfunction,

endometrial causes like local inflammation, iatrogenic caused by medications or devices like IUDs, and not yet classified.

What's the most common reason behind AUB?

By far, the majority is linked to ovulatory dysfunction, basically, not ovulating regularly.

This is really common in adolescents just starting their periods and in women approaching menopause.

Why does lack of ovulation cause bleeding issues?

Without ovulation, you don't get the corcus luteum forming, which means you don't get the progesterone surge needed to stabilize the uterine lining after estrogen is built it up.

So you have this unopposed estrogen effect, the lining gets thick and unstable, and then it sheds irregularly and often heavily.

Ah, I see.

Conditions like PCOS, obesity, thyroid problems often disrupt ovulation.

Exactly.

They're major contributors.

Treatment aims to manage the bleeding NSAIDs can help.

Hormonal therapies like birth control pills or the LNG -IUD are very effective.

Sometimes procedures like ablation or hysterectomy are needed if bleeding is severe and fertility isn't desired.

And a critical point, any post -menopausal bleeding needs investigation for cancer.

Let's shift to polycystic ovary syndrome, PCOS.

You mentioned it's common and affects fertility.

Hugely common, one of the most frequent endocrine disorders in women, and a leading cause of infertility.

It's complex.

What are the key diagnostic features?

Diagnosis usually needs at least two out of three things.

First, irregular ovulation or no ovulation.

Second, clinical signs or blood tests showing high androgen levels, things like hirsutism or acne.

And third, polycystic appearing ovaries on ultrasound.

But you don't have to have the polycystic ovary.

Correct.

And having polycystic ovaries alone doesn't mean you have PCOS.

It's a diagnosis of exclusion too.

You have to rule out other things that could cause similar symptoms.

What's the underlying mechanism?

Figure 35 .5 talks about insulin resistance.

Yes, that's absolutely central.

There's often a genetic predisposition, maybe lifestyle factors like obesity play a role.

But the core issue involves insulin resistance.

The body cells don't respond properly to insulin, so the pancreas pumps out more hyperinsulinemia.

And high insulin affects the ovaries?

Exactly.

High insulin levels directly stimulate the ovaries to produce more androgens, like testosterone.

It also reduces levels of a protein called sex hormone -binding globulin, SHBG, which means more free active testosterone is circulating.

Is that causes the hirsutism and acne?

Right.

And the hormonal imbalance, with relatively low FSH and high LH, disrupts normal follicle development.

Follicles start to grow, but they don't mature properly or ovulate, leading to those multiple small cysts you might see on ultrasound.

Figure 35 .4 shows that typical enlarged ovary with a smooth, pearly white capsule.

What are the main clinical signs someone might experience?

Box 35 .3 lists them.

They often show up within a couple of years of puberty or sometimes later after a period of normal cycles.

You see dysfunctional uterine bleeding or mannuria, hirsutism, acne, sometimes a skin darkening called acanthosis nigricans,

and infertility.

And it's linked to other health risks?

Definitely.

Women with PCOS are often overweight or obese and have higher rates of hypertension, dyslipidemia, sleep apnea.

And importantly, they have a significantly increased risk of developing metabolic syndrome and type 2 diabetes as they get older.

Plus, a higher risk for uterine cancer later on due to that prolonged unopposed estrogen.

How is PCOS managed?

Treatment focuses on the symptoms and long -term risks.

Combined oral contraceptives, COCs, are often used to regulate cycles and reduce androgen effects.

Lifestyle changes, weight loss, exercise are crucial for improving insulin sensitivity.

Metformin and insulin sensitizer is also commonly used.

Okay.

Quickly on premenstrual disorders, PMS and PMDD, common, but what's the difference?

Both involve a cyclical pattern of distressing physical, psychological, or behavioral symptoms that pop up in the luteal phase the week or two before the period and significantly interfere with life.

PMDD, premenstrual dysphoric disorder, is the really severe end of the spectrum.

What causes them?

It's complex and not fully understood.

It seems to involve an abnormal response or increased sensitivity to the normal fluctuations of ovarian hormones, possibly interacting with neurotransmitters like serotonin and GABA in the brain, affecting mood and behavior.

Stress, genetics, lifestyle factors likely play a role too.

The symptoms in box 35 .4 for PMDD what stands out?

For PMDD, the emotional symptoms are usually the most prominent and distressing things like severe depression, anger, irritability, anxiety, fatigue.

Physical symptoms like bloating or breast tenderness might be there, but are often less problematic than the mood changes.

Treatment is often symptomatic lifestyle changes, sometimes OCPs to regulate the cycle or SSRI antidepressants.

Let's move to infection and inflammation.

Starting with pelvic inflammatory disease, PID, we mentioned STIs.

Yes, PID is an acute inflammation of the upper genital tract uterus, tubes, sometimes ovaries, usually caused by an infection descending from the lower tract, and the most common culprits by far are untreated STIs, especially chlamydia and gonorrhea.

What puts someone at higher risk?

Having multiple partners, previous PID being sexually active before 25, douching, basically anything that increases exposure to STIs or disrupts the natural vaginal environment.

How does the infection cause damage?

You mentioned scarring.

Right, the microorganisms trigger inflammation, swelling.

In the fallopian tubes, cell pangitis, this can cause obstruction and necrosis.

Chlamydia is particularly nasty for causing silent scarring.

Figure 35 .7 shows advanced cell pangitis, maybe even piocell pings where the tubes are swollen with pus and adhesions formed.

And the long -term consequences.

Infertility due to tool blockage, a much higher risk of ectopic pregnancy, chronic pelvic pain, even potentially life -threatening complications if the infection spreads.

Symptoms can be vague, though.

Very variable.

Some women are asymptomatic, others have severe lower abdominal pain, often bilateral, maybe pain with sex or urination, irregular bleeding.

Diagnosis often relies on clinical findings like cervical motion tenderness, box 35 .5 lists criteria, treatment needs to be prompt, broad spectrum antibiotics, and partner treatment is crucial.

Okay, what about vaginitis, just general vaginal inflammation?

Essentially, yes, irritation or inflammation causing itching, burning, odor, or abnormal discharge can be caused by infections, bacterial vaginosis, which is actually an overgrowth of normal bacteria, not strictly an infection, yeast infections, Candida, or STIs like trichomoniasis, or even non -infectious things like irritants or low estrogen after menopause, atrophic vaginitis.

And the key is often pH balance.

Often, yes.

The vagina is normally acidic, pH 4 to 4, 4 .5, which helps keep harmful bacteria in check.

Anything that raises the pH semen, douching soaps, even antibiotics, can disrupt that balance and allow problematic organisms to flourish.

Quickly, cervicitis.

Inflammation of the cervix, often caused by STIs too.

Key signs are a yellowish pus -like discharge and easy bleeding from the cervix.

It can be a find at PID.

And vulvadenia, chronic pain.

Yes.

VV is chronic vulvar.

Pain, burning, stinging, soreness lasting over three months, without an obvious infection or skin disease.

The cause is often unknown, likely multifactorial, involving nerve pathways, inflammation, maybe even genetics.

Treatment is tricky, often involving avoiding irritants, topical treatments, sometimes physical therapy or medications.

And berthelinitis.

Those glands near the vaginal opening.

Figure 35 .8 shows them.

Right.

The Bartholin glands.

If the duct gets blocked, usually due to infection, it can swell up into a painful cyst, sometimes an abscess, often needs antibiotics and drainage.

Moving on to pelvic organ prolapse, POP.

What's happening here?

Basically, the scaffolding holding the pelvic organs in place, the muscles and connective tissues fascia gets weakened or damaged.

So one or more organs can descend or bulge into the vagina.

Main cause is childbirth.

That's a major one, yes.

Direct trauma during delivery.

But also aging, obesity, chronic straining from constipation, even genetics play a role.

Can you describe the different type, like uterine prolapse and figure 35 .9?

Sure.

Uterine prolapse is the cervix, or the whole uterus, dropping down into the vaginal canal.

It's graded.

Grade 1 is minimal.

Grade 3 is severe, where the cervix might actually protrude outside the body.

And cystoseal and rectoseal.

Figure 35 .10 shows these.

Right.

A cystoseal is when the bladder bulges downward into the front wall of the vagina.

A rectoseal is when the rectum bulges forward into the back wall of the vagina.

What symptoms do they cause?

Often a feeling of pressure or fullness in the vagina, like something is falling out.

Cystoseal might cause urinary issues, like difficulty emptying the bladder.

A rectoseal can make bowel movements difficult.

Sometimes women even have to manually push on the bulge to have a bowel movement.

How are these treated?

Box 35 .7 mentions options.

Non -surgically, a pessary can be used as a device inserted into the vagina to support the organs.

Kegel exercises help strengthen the pelvic floor, maintaining a healthy weight, preventing constipation are key.

Estrogen therapy can help post -menopausal women.

Surgery is usually the last resort.

And the chapter had that important, did you know, about vaginal mesh?

Yes, a really crucial point.

Mesh was used for surgical repair, but caused serious complications like chronic pain, erosion, infection for many women.

The FDA eventually ordered manufacturers to stop selling it for transvaginal POP repair in 2019 because the risks outweigh the benefits for that specific use.

Okay, let's turn to benign growths and proliferative conditions.

Not cancer, but still growths.

Benign ovarian cysts seem common.

Very common, especially during reproductive years when hormone levels fluctuate.

Most are functional cysts related to the normal menstrual cycle.

Like what?

Well, you can have a folliculocyst where the dominant follicle just doesn't rupture to release the egg or other follicles don't regress properly.

Or a corpus luteum cyst where the structure left after ovulation persists and fills with fluid.

These usually resolve on their own, but can cause pain or menstrual irregularities.

Figure 35 .11 shows a typical cyst, just a fluid -filled sac.

Exactly.

Sometimes, though, you can get dermoid cysts, teratomas, which are fascinating.

They arise from germ cells and can contain things like hair, skin, even bone.

They have a small malignant potential.

And rarely a large cyst can cause the ovary to twist on its supporting ligament's ovarian torsion, cutting off blood supply.

That's a surgical emergency.

These are benign growths of the uterine lining tissue, little stalks of tissue sticking out into the uterine cavity, often linked to hormonal factors, obesity, tamoxifen use.

They are a common cause of abnormal bleeding, especially intermenstrual bleeding, usually removed easily.

And leomyomas, or fibroids, extremely common too.

Incredibly common.

Maybe 70 -80 % of women have them by age 50, though many are asymptomatic.

They are benign, smooth muscle tumors of the uterus.

What causes them?

Figure 35 .33 shows their appearance.

The exact cause isn't known, but they are definitely hormone -sensitive, especially to estrogen and progesterone.

They tend to grow during pregnancy and shrink after menopause.

Risk factors include genetics, race, more common in earlier onset in blad women, obesity, PCOS.

Figure 35 .33 shows that typical world fibrous appearance.

They can be located just under the outer surface, subcerosal, within the uterine wall, intramural, or bulging into the cavity, submucous.

What symptoms can they cause?

Depends on size and location.

Abnormal bleeding is very common.

Pain can occur, especially if a fibroid outgrows its blood supply.

Large fibroids can cause pressure symptoms, bladder frequency, constipation.

They can sometimes interfere with fertility or childbirth.

How are they treated?

Often just observation to face symptomatic.

Hormonal contraceptives can manage bleeding.

Medications like GnRH agonists can shrink them temporarily.

Surgical options range from myomectomy, removing just the fibroids, preserving the uterus, to hysterectomy.

Other options include uterine artery embolization, UAE, which cuts off blood supply, or ablation techniques.

Briefly, adenomyosis, endometrial tissue in the muscle wall.

Exactly.

Glans and stroma from the endometrium burrow into the myometrium, the muscular wall of the uterus, can cause heavy painful periods, uterine enlargement, chronic pain, often diagnosed definitively only after hysterectomy.

And endometriosis tissue outside the uterus.

Right.

This is functioning endometrial tissue found in implants outside the uterus commonly on the ovaries, pelvic peritoneum, ligaments, bowel, bladder.

Figure 35 .14 shows examples, like those dark powder burn lesions.

How does it get there?

Retrograde menstruation.

That's the most widely accepted theory.

Menstrual fluid containing endometrial cells flows backward through the fallopian tubes into the pelvic cavity.

But not everyone with retrograde flow gets endometriosis.

So other factors like immune response, genetics, maybe cell transformation must be involved.

And how does it cause problems?

Because this ectopic tissue responds to hormonal cycles, it proliferates, breaks down and bleeds just like the uterine lining.

But the blood has nowhere to go, causing inflammation, scarring, adhesions, and chronic pain.

It's estrogen dependent, but interestingly, the lesions often show resistance to progesterone.

Key symptoms.

Can mimic lots of things.

But classic symptoms include significant pelvic pain, especially with periods, dyspereunia, painful intercourse, dyskesia, painful bowel movements, infertility, a major issue, and sometimes abnormal bleeding.

Importantly, the severity of symptoms doesn't always correlate with the amount of disease seen visually.

Diagnosis and treatment.

Diagnosis is often suspected based on symptoms, but definitive diagnosis usually requires laparoscopy to directly visualize the implants.

Treatment aims to manage pain and improve fertility.

Options include hormonal therapies to suppress ovulation, OCPs, GnRH agonists, progestins like the LNG -IUD, or surgical removal of the implants.

Recurrence is common, unfortunately.

Let's move into cancer, starting with cervical cancer.

Okay.

The incidence has dropped dramatically thanks to the PAP test, but it's still a major issue globally.

The overwhelming cause, almost exclusively, is persistent infection with high -risk strains of the human papillomavirus, HPV, especially type 16 and 18.

What increases the risk besides HPV?

Things that increase exposure or persistence,

multiple sexual partners, early age at first intercourse, high parity, immunosuppression, long -term oral contraceptive use, smoking.

How does HPV actually cause the cancer?

Figures 35 .15 and 35 .16 are relevant here.

HPV infects the basal cells right at the transformation zone of the cervix, where the squamous cells of the outer cervix meet the glandular cells of the inner canal.

Figure 35 .15 shows these cell types.

This zone is really vulnerable.

The virus integrates its DNA into the host cells, disrupting normal cell cycle control.

Figure 35 .16 shows the progression from normal cells to low -grade changes, CINI or LSIL, then potentially high -grade changes, CIN3 or HISIL, which is carcinoma in situ, and finally invasive cancer.

Most infections clear, but persistent ones can progress over years.

Symptoms.

Often asymptomatic in early stages, which is why screening is vital.

If symptoms occur, it's usually abnormal bleeding, postcoital, intermenstrual or postmenopausal or unusual vaginal discharge.

Advanced disease causes pain, urinary or rectal issues.

Evaluation and Treatment.

Box 35 .8 mentions screening guidelines.

Evaluation involves PAP and HPV testing.

Guidelines vary by age.

Box 35 .8 details USPSTF recommendations, possibly colposcopy and biopsy if abnormalities are found.

Treatment depends heavily on the stage, table 35 .3, ranging from procedures for precancerous lesions to surgery, radiation and chemo for invasive cancer.

And the did you know on prevention?

Yes.

HPV vaccination is key primary prevention.

Gardasil -9 protects against the most common cancer -causing types.

It's recommended for boys and girls around age 11 -12, but can be given later.

It prevents not just cervical cancer, but also other HPV -related cancers like anal, throat, vulvar, vaginal and penile cancers.

Consistent condom use also reduces transmission.

What about other gynecologic cancers?

Vaginal cancer.

It's rare.

Often linked to HPV as well, similar risk factors to cervical cancer.

Most common type is goimicelle carcinoma, usually in older women.

Often asymptomatic until late, main symptom is abnormal bleeding.

Vulvar cancer.

Affects the external female genitalia, most often the labia majora.

Incidence is increasing.

Again, mostly goimicelle carcinoma, often linked to HPV, especially type 16, or chronic inflammation.

Early detection is crucial.

Endometrial cancer, the most common gynecologic malignancy.

Yes, cancer of the uterine lining.

Most common in postmenopausal women, typically late 50s, early 60s.

Incidence is rising, possibly linked to obesity trends.

What's the main risk factor?

Prolonged exposure to unopposed estrogen.

Think estrogen -only hormone replacement therapy?

Tamoxifen use, conditions causing chronic inovulation like PCOS, obesity, fat cells produce estrogen, early menarche, late menopause, nulliparity.

Figure 35 .18 visually links obesity, diet, activity level to risk.

How does estrogen drive it?

Figure 35 .19 helps explain.

Estrogen stimulates the endometrium to grow, proliferate.

Progesterone normally counteracts this.

In situations with unopposed estrogen, you get excessive growth, hyperplasia, which can eventually become atypical and progress to cancer.

Type I endometrial cancer, the most common type.

Figure 35 .19 shows how estrogen signaling promotes growth, while progesterone signaling normally inhibits it.

Key symptom.

Abnormal vaginal bleeding, especially any bleeding after menopause, is the cardinal sign.

Needs immediate evaluation, usually starting with transvaginal ultrasound to measure endometrial thickness, followed by biopsy if needed.

Endovarian cancer, often diagnosed late.

Tragically, yes.

It has high mortality because early symptoms are often vague or absent, and we lack effective screening tests for the general population.

Most cases occur in women over 65.

Risk factors.

Table 35 .6 lists many.

Advancing age is key.

Genetics play a major role mutations in BRCA1 and BRCA2 significantly increase risk, as does Lynch syndrome.

Family history is important.

Factors increasing lifetime ovulation cycles, early menarche, late menopause, nulliparity, increase risk.

Conversely, factors that suppress ovulation, pregnancy, breastfeeding, OCPs, are protective.

Obesity, MHT, endometriosis also increase risk.

What about the origin?

Figure 35 .21 touches on this.

Ovarian cancer is very heterogeneous.

Figure 35 .21 shows the different cell types in the ovary where tumors can arise.

Epithelial, germ cell, stromal.

But the really groundbreaking finding in recent years is that many high -grade serous ovarian cancers, the most common and lethal type actually seem to originate not in the ovary itself, but in the fimbriated end of the fallopian tube.

This has huge implications for prevention strategies in high -risk women, like considering removal of the tubes, selpidectomy, along with or instead of the ovaries.

Why is it often caught late?

Symptoms.

Early symptoms are notoriously non -specific gloating, feeling full quickly, abdominal or pelvic discomfort, changes in bowel or bladder habits, often dismissed as GI issues.

By the time more specific symptoms like a pelvic mass,

significant abdominal swelling, the sites or pain develop, the cancer has often spread, metastasized, as shown in figure 35 .22.

Evaluation and treatment.

There's no effective routine screening like the PAP test.

CA -125 blood test and ultrasound aren't specific enough for general screening.

Diagnosis involves imaging,

CT, MRI, PET, and ultimately surgical exploration for staging Table 35 .7.

And debulking, removing as much tumor as possible.

Treatment that involves chemotherapy, sometimes targeted therapies or radiation.

Let's shift gears to sexual dysfunction.

How is it defined?

It's broadly defined as a lack of satisfaction with sexual function, stemming from pain or deficiency in desire, arousal, or orgasm.

It's very common, maybe affecting up to 45 % of adult women, and its complex biological, psychological, relational, cultural factors all intertwine.

What are the common types?

Hypoactive sexual desire disorder, low libido, is probably the most common.

Causes can range from depression and relationship issues to hormonal factors, like low testosterone, or medication side effects.

And orgasmia, inability to orgasm, can be linked to chronic illness, nerve issues, medications.

Dysperia, painful intercourse, is also common, could be due to lubrication issues, infections, pelvic disorders, thinning tissues after menopause.

And vaginismus is involuntary muscle spasm, preventing penetration, often linked to fear or past trauma.

Treatment needs to be holistic.

Absolutely.

It's crucial to look at the whole picture of physical health, mental health, relationship dynamics.

Sometimes it's addressing an underlying medical issue, sometimes it's therapy, sometimes medication.

But a sensitive, comprehensive approach is key.

Moving to impaired fertility affects many couples.

Yes, about 15 % of couples face infertility, defined as inability to conceive after a year of trying.

Causes can be male factor, female factor, or both.

What are the main female factors?

Roughly 40 % involve ovulatory disorders, hormonal imbalances, age -related decline in egg quality.

About 20 % involve reproductive tract abnormalities, especially tubal factors.

Scarring or blockage of the fallopian tubes, often from past pelvic infections like chlamydia or gunnery, is a major cause.

Adhesions from endometriosis or surgery can also block tubes.

Uterine factors like fibroids or problems with the lining can also play a role.

How is it evaluated?

It starts with a thorough history, then usually least invasive tests first, semen analysis for the male partner, checking female hormone levels, pelvic exam, ultrasound.

A histrosol pentagram, HSG, uses dye and x -ray to check if the fallopian tubes are open.

And assisted reproductive technologies, RT.

RT like IVF have helped countless couples conceive.

But the chapter how it's ongoing questions about potential long -term health effects for conceives children, higher rates of multiples, preterm birth, and possibly a slightly higher rate of certain birth defects.

The takeaway message though is the vital importance of preventing STIs to preserve fertility in the first place.

Okay, our final major section,

disorders of the female breast, starting with galacturia.

This is inappropriate lactation, milky discharge from the breast when a woman isn't pregnant or breastfeeding.

It's not related to breast cancer.

What causes it?

It's usually a sign of an underlying hormonal imbalance, most often hyperprolactamemia.

Too much prolactin.

This can be caused by pituitary tumors, prolactinomas,

certain medications, hypothyroidism, chronic stress, even nerve issues triggering the suckling reflex pathway.

Evaluation involves checking hormone levels, prolactin, thyroid, and possibly pituitary imaging.

Treatment targets the underlying cause.

Now, benign breast disease, BBD, lots of non -cancerous changes.

Yes, a whole spectrum.

Common symptoms prompting evaluation are pain, a palpable mass, or nipple discharge.

Most turn out benign.

But the type of benign change matters for future cancer risk.

Can you break down the classification?

Sure.

First are non -proliferative lesions.

These do not increase cancer risk.

Think simple cysts, very common fluid -filled sacs, mild hyperplasia.

The old term fibrocystic changes falls here but is very specific.

Okay, no increased risk there.

Then.

Proliferative lesions without atypia.

Here, there's increased cell growth, but the cells look normal.

Examples include usual ductal hyperplasia, UDH, interductal papillomas can cause nipple discharge,

sclerosing adenosis, radial scars, and simple fibroadenomas, common benign solid lumps in younger women.

These generally have no or only a very slight increase in cancer risk.

And the category with significant risk.

Proliferative lesions with atypia, also called atypical hyperplasia, AEH.

This includes atypical ductal hyperplasia, AEH, and atypical lobular hyperplasia, ALH.

Here you have increased cell growth plus some abnormal -looking cells, atypia.

Finding AEH significantly increases breast cancer risk, maybe four -fold or more.

It acts as a marker for increased risk in both breasts.

How are these evaluated?

Mammography comes in here.

The evaluation uses a combo physical exam, mammography, ultrasound, sometimes MRI, and biopsies are needed for diagnosis.

The chapter has a really important did you know on screening mammography.

What are the key points there?

Benefits and harms.

The benefit is early detection, which can lead to less aggressive treatment and improved survival.

But there are harms.

False positives are common, leading to anxiety and more tests.

And overdiagnosis is a major issue finding cancers,

especially ductal carcinoma in situ,

DCIS, that might be so slow growing that would never have caused harm in a woman's lifetime.

This leads to over -treatment, surgery, radiation, for a disease that might not have needed it.

And breast density.

Figure 35 .29 shows this.

Right.

Mammograms rely on seeing tumors against a fatty background, which looks dark.

Dense breast tissue, glands, and connective tissue looks white on a mammogram, just like tumors do.

So, as figure 35 .29 illustrates, in dense breasts, category C and D, it can be much harder to spot a cancer like finding a snowball in a snowstorm.

High breast density is also an independent risk factor for developing breast cancer.

Which leads us to breast cancer itself.

Most common cancer in American women, excluding skin cancer, second leading cause of cancer death.

Its multifactorial reproductive history, hormones, environment, genetics, all interact.

Let's unpack some key factors.

Reproductive factors.

Pregnancy.

It's complex.

Having your first child at a younger age is protective long term.

But there's a temporary increase in risk in the years immediately following a pregnancy.

Pregnancy -associated breast cancer, PBC.

Overall, though, women who have children generally have a lower lifetime risk than women who don't, especially if they have them young.

What about lobular involution?

The aging breast.

Figures 35 .25 and 35 .26.

This is critical.

The functional units of the breast are terminal duct lobular units, TDLUs.

That's where most cancers start, figure 35 .25 shows this.

With age, these lobules normally regress, or involute, replaced by fat.

This involution is protective.

Delayed involution is a major risk factor.

Figure 35 .26 highlights how the tissue environment, extracellular matrix, changes during involution after lactation and how this process, while normal, can sometimes create an environment that promotes tumor growth if abnormal cells are present.

Hormonal factors seem central, figure 35 .27 and 35 .28.

Absolutely crucial.

Figure 35 .27 shows how hormones drive breast development.

More menstrual cycles, early menarche, late menopause, mean more hormone exposure, increasing risk.

Most breast cancers are hormone receptor positive, ER plus PR plus.

Figure 35 .28 is key.

It shows how estrogen isn't just systemic, it can be produced locally within the breast tissue itself by enzymes like aromatase.

This local production can fuel tumor growth even after menopause when circulating levels are low.

And hormone therapy.

Oral contraceptives.

Combined estrogen -progesterone -MHT definitely increases risk.

Estrogen -only MHT seems less risky for breast cancer, but increases endometrial cancer risk.

Combined OCP slightly increased breast cancer risk while women are taking them, but this decreases after stopping.

They are protective against ovarian and endometrial cancer.

What about lifestyle and environment?

Mammographic density is a strong risk factor.

Radiation exposure, especially at young ages, increases risk.

Alcohol intake consistently increases risk.

Obesity, particularly post -menopausal obesity, increases risk.

Fat tissue produces estrogen via aromatase.

Physical activity is protective, diet is complex, but high fiber may be protective, while processed meats may be increased risk.

Environmental chemicals that mimic estrogen, xenoestrogens, are a concern.

Inherited risk.

BRCA genes.

Yes, about 5 -10 % of breast cancers are linked to inherited mutations.

BRCA1 and BRCA2 are the most well -known, conferring very high lifetime risks of dressed and ovarian cancer.

Family history is a major risk factor, even without a known mutation.

Pathophysiology, how does it develop and spread?

Figures 35 .33.

Most are adenocarcinomas, starting in the ducts or lobules as carcinoma in situ, CIS.

Invasive cancers break through the basement membrane.

Breast cancer is incredibly heterogeneous genetically.

The tumor microenvironment, figures 35 .30 -35 .31, is critical cancer cells interact with surrounding stromal cells, immune cells, blood vessels to promote growth, invasion, and metastasis.

Invasion can happen as collective cell migration or single cells undergoing EMT, figure 35 .32.

Metastasis involves getting into and out of blood limb vessels.

Figure 35 .33 shows vascular mimicry, where tumor cells themselves can form vessel -like channels, aiding spread.

Let's clarify ductal carcinoma in situ, DCIS.

Figure 35 .34 shows it.

DCIS means cancer cells are confined within the breast ducts, figure 35 .34.

They haven't invaded surrounding tissue.

Mammography has led to an epidemic of DCIS diagnoses.

The perspective is shifting.

DCIS is often seen now as a non -obligate precursor or risk factor for invasive cancer, rather than state zero cancer itself.

There's huge debate about overdiagnosis and over -treatment, especially for low -grade DCIS.

And lobular carcinoma in situ, LCIS.

LCIS originates in the lobules.

The cells are discohesive, lack echidherin.

It's usually an incidental finding, not seen on mammograms.

LCIS isn't considered a direct precursor, but a significant marker of increased risk – about 25 -35 % over decades – for developing invasive cancer in either breast.

Management is often close surveillance, possibly risk -reducing meds like tamoxifen or prophylactic mastectomy.

Finally, clinical manifestations of invasive breast cancer.

Table 35 .11 and Figure 35 .35.

The first sign is usually a painless lump or thickening, often in the upper outer quadrant.

Other signs, Table 35 .11, can include palpable axillary lymph nodes, skin -dippling nipple retraction, Figure 35 .35 shows this, skin changes like redness or edema, poterange, nipple discharge, or sometimes pain in advanced stages with metastasis.

Evaluation involves imaging, biopsy and testing tumor characteristics, hormone receptors, HER2 status, genomic profiling to guide treatment, surgery, radiation, chemo, hormonal therapy, target therapy.

Wow, okay.

We have covered an absolutely immense amount of ground today.

From the very formation of the reproductive system, through maturation, hormonal cycles, infections, growths, complex cancers, and impacts on function and fertility.

It's a huge chapter.

And these are really fundamental processes.

Understanding the pathophysiology, you know, how things can go wrong at a cellular or hormonal level is just so crucial.

It's not just academic knowledge.

Right.

It helps you make sense of health information, maybe recognize potential signs earlier, and just feel more empowered when talking with health care providers.

Exactly.

It helps you ask better questions and participate more actively in decisions about your own health or the health of people you care about.

So reflecting on all these interconnected systems, hormones influencing everything from puberty to cancer risk, inflammation, driving infertility, what's a provocative thought for our listeners?

Maybe.

Considering these complex links, what surprising connections or ripple effects might we uncover next as research continues?

That's a great question.

The interplay between systems, immune, endocrine, metabolic, is clearly vital.

And we're likely just scratching the surface in understanding how disruptions in one area echo throughout the body, especially in female reproductive health.

There's so much more to learn.

Definitely something to keep thinking about.

Well, from the entire Last Minute Lecture team, thank you so much for joining us on this deep dive into all creations of the female reproductive system.

Thanks for listening.